Clinical Trials Logo

Filter by:
NCT ID: NCT06372626 Recruiting - Clinical trials for Neuroendocrine Carcinoma

Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

Start date: May 30, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The trial is divided into two parts. PART 1 is a dose escalation study of the ZG005 combined with Etoposide and Cisplatin, primarily assessing the tolerability and safety of this combined treatment. PART 2 is a dose expansion study, further evaluating the preliminary efficacy and safety of this combined treatment.

NCT ID: NCT06372548 Recruiting - Amblyopia Clinical Trials

Rehabilitation Training Games for Children With Amblyopia

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

A gamification product was developed to guide children with amblyopia to develop rehabilitation training habits by combining cognitive evaluation theory and occlusion therapy. A randomized controlled trial was conducted to examine the ease of use, acceptability and treatment compliance of the game.

NCT ID: NCT06372236 Recruiting - Clinical trials for Conditions or Focus of Study: B7-H3 Positive Relapsed/Advanced Malignant Solid Tumor

UTAA06 Injection for Treatment of Advanced Malignant Solid Tumors

Start date: December 1, 2023
Phase: Phase 1
Study type: Interventional

This is a single-arm, open, early-stage clinical study. The main purpose of this study is to explore the maximum tolerated dose (MTD), the optimal phase II recommended dose, safety, initial anti-tumor activity, cytopharmacokinetics, immunogenicity, biomarkers and other characteristics of drug therapy in patients with advanced malignant solid tumors. Eligible subjects were transfused with UTAA06 injection after pretreatment, and their blood was collected before and after infusion for evaluation of cytopharmacokinetics, safety, immunogenicity and biomarkers. In this study, tumor evaluation was mainly performed using RECISTv1.1. In addition to the baseline period, the therapeutic efficacy was evaluated at the frequency of Q3m during 4w, 2m, 3m, and 6-24m after cell infusion. Tumor evaluation was performed until disease progression (PD), new anti-tumor therapy, death, intolerable toxicity, investigator's decision, or patient's voluntary withdrawal. Whichever comes first.

NCT ID: NCT06372223 Completed - Clinical trials for Advanced Solid Tumor

A Food Effect Study of SPH5030 Tablets.

Start date: March 4, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the food effect of SPH5030 tablets in healthy Chinese adult subjects.

NCT ID: NCT06372184 Not yet recruiting - Rhinitis, Allergic Clinical Trials

Washed Microbiota Transplantation for Allergic Rhinitis

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

Allergic rhinitis (AR) is characterized by sneezing, nasal congestion, nasal itching and nasal leakage and is caused by immunoglobulin E (IgE)-mediated reactions to inhaled allergens. Increasing evidence showed that gut microbiota could influence the development of AR, and we found that washed microbiota transplantation (WMT) could improve nasal symptoms in clinical practice. This clinical trial aims to evaluate the efficacy and safety of WMT for AR.

NCT ID: NCT06372145 Recruiting - Clinical trials for Relapsing Multiple Sclerosis

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

Start date: April 16, 2024
Phase: Phase 3
Study type: Interventional

This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥18 years) with RMS, PPMS, or NRSPMS who were previously enrolled in the Phase 2b LTS (LTS16004) or 1 of the 4 Phase 3 tolebrutinib pivotal trials (GEMINI 1 [EFC16033], GEMINI 2 [EFC16034], HERCULES [EFC16645], or PERSEUS [EFC16035]). SUBSTUDY: ToleDYNAMIC substudy

NCT ID: NCT06371586 Recruiting - Gastric Cancer Clinical Trials

Neo-Sequence 2:NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC

Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

The regimen of Albumin paclitaxel+SOX+BEV neoadjuvant therapy lasted for 6 cycles, during which PD-1 monoclonal antibody therapy was interspersed for 4 cycles for locally advanced diffuse gastric cancer.

NCT ID: NCT06371534 Not yet recruiting - Tumor Clinical Trials

A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults

Start date: April 2024
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to compare the pharmacokinetic and safety similarity of QL2109 with DARZALEX FASPRO® in healthy male volunteers. Participants will receive a single injection of QL2109/ DARZALEX FASPRO® Researchers will compare pharmacokinetic, safety, and immunogenic similarities between the two groups.

NCT ID: NCT06371482 Recruiting - SCLC, Limited Stage Clinical Trials

Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)

Start date: June 1, 2023
Phase: Phase 2
Study type: Interventional

This trial aims to assess efficacy and safety of durvalumab combined with chemoradiotherapy for limited stage small cell lung cancer.

NCT ID: NCT06371326 Enrolling by invitation - Clinical trials for Overweight or Obesity

A Study of ZT002 Injection in Participants With Overweight or Obesity

Start date: November 21, 2023
Phase: Phase 1
Study type: Interventional

This study will comprise a randomized, double-blind, placebo-controlled, multiple-ascending-dose, safety, tolerability, and pharmacokinetics study of ZT002 in participants with Overweight or Obesity.